• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Beta Blockers and Depression: The Controversy Revisited
RESEARCH UPDATE

Beta Blockers and Depression: The Controversy Revisited

December 31, 2020
Sean Ransom, Ph.D
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sean Ransom, Ph.D Dr. Ransom has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Agustini B et al, J Hum Hypertens 2020;34(11):787–794

Study Type: Cross-sectional

Antihypertensives are among the world’s most widely prescribed drugs, but many of them impact pathways associated with depression. Beta blockers have long been believed to cause depression, but most of the studies suggesting this were carried out decades ago and their findings have been inconsistent. Other classes, like angiotensin-receptor blockers, are associated with lower rates of depression, albeit with weaker evidence.

In this multinational study, researchers examined mood outcomes in 14,195 hypertensive adults over age 65 who did not have heart disease. Depressive symptoms were measured with the self-reported Centre for Epidemiological Studies-Depression (CESD-10) scale. Each class of antihypertensive drugs was tested against the other classes and against a group of unmedicated hypertensive patients to see whether any class was associated with an increased risk of clinically significant depressive symptoms.

Patients who took beta blockers were more likely to meet or exceed the clinical cutoff score of 8 on the CESD-10 scale, a sign of clinically significant depressive symptoms, than those who took other antihypertensive drugs. Numerically, 13.4% of patients who used beta blockers showed clinical elevations in depression, whereas between 10.2% and 10.5% of patients who used other antihypertensives showed this elevation. Logistic regression analysis showed that this difference was indeed significant, even when controlling for numerous factors that included gender, age, and smoking history. Other classes of antihypertensives, including angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, and calcium-channel blockers, were not associated with depression.

The researchers also compared the beta blockers based on their selectivity for the β-receptor and their lipophilic properties. Lipophilic medications are more likely to cross the blood-brain barrier, and the more lipophilic beta blockers like propranolol and metoprolol were associated with a higher risk of depression than hydrophilic ones like atenolol. Meanwhile, the more selective beta blockers were less depressogenic, which weakens the argument that blockade at this receptor plays a causative role in depression.

TCPR’s Take
The fact that beta blockers were associated with depression while other antihypertensives were not gives us pause, but the risk here is very small (3%). If beta blockers must be used in depressed patients with hypertension, stick with atenolol. Whether this risk translates to the psychiatric use of propranolol—which generally involves lower doses and normotensive patients—remains unanswered.
General Psychiatry
KEYWORDS alpha-agonists beta-blockers guanfacine medical_comorbidities psychosomatics research-update
    Sean Ransom, Ph.D

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Beta Blockers and Depression: The Controversy Revisited
    The Queen’s Gambit
    How to Use Lamotrigine
    Probiotics in Psychiatry
    Rest Easy: Benzos, Z-Drugs, and Dementia
    CME Post-Test - Mind-Gut Connection, TCPR, January 2021
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.